Acne vulgaris. Acne vulgaris
Conditions
Interventions
Intervention 1: The case group, will receive semisolid formulation of metformin, twice a day, for two months and Azithromycin 250mg caplet will be used every other day. Intervention 2: The control gro
Treatment - Drugs
Placebo
The case group, will receive semisolid formulation of metformin, twice a day, for two months and Azithromycin 250mg caplet will be used every other day.
The control group will receive the base of semisolid formulation, the preparation will be administrated topically , two times in a day and for two months and Azithromycin 250mg caplet will be used eve
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria:Patients with mild to moderate acne, defined as a score of 1 to 30 on the global acne grading system (GAGS) scale, who did not get any treatment before, or were not satisfied with their previous acne therapies, will be participated in the study after giving written informed consent. Exclusion criteria: Patients will be excluded if they are diabetic or have an uncontrolled systemic disease; have received topical anti acne therapy two months before or during the study or any systemic therapy, 30 days before or during the study; were known to be allergic or sensitive to any of the study medications or their components; have a skin disease that might interfere with the diagnosis or evaluation of their skin lesions; pregnant women and lactating ones.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin lesions. Timepoint: 0 , 4 , 8 weeks. Method of measurement: Observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients satisfaction. Timepoint: 0,4,8 weeks. Method of measurement: determined by a 10 point scale ranging. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Nasrin Saki
Shahid Faghihi Skin and Dermatology Clinic- Shiraz-Iran
Outcome results
None listed